{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-23-000019","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.819396+00:00","generated_at":"2026-06-16T02:34:06.244860+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lexicon amends Oxford loan: third tranche raised to $75M, adds minimum cash covenant","bullets":["Third tranche increased from $50M to $75M; fourth tranche reduced to $25M (subject to Oxford's consent).","New minimum cash covenant effective after third tranche funding; unused fee if full tranche not drawn.","Revenue covenant tied to sotagliflozin net product revenue milestones after FDA approval.","Minimum cash test dates deferred based on achieving net-proceeds milestones from partnering or financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-23-000019","json":"https://secwatch.observer/filing/0001062822-23-000019.json","markdown":"https://secwatch.observer/filing/0001062822-23-000019.md","text":"https://secwatch.observer/filing/0001062822-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000019/0001062822-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000019/lxrx-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:34:06.244860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a0b60c27f98d4e87520273b63aaaf966153fa4b","claim":"LEXICON PHARMACEUTICALS, INC. amended Second Amendment to Loan and Security Agreement with Oxford Finance LLC valued at Third tranche increased from $50M to $75M; fourth tranche decreased from $50M to $25M; minimum cash (effective 2023-05-01).","evidence_excerpt":"On May 1, 2023, Lexicon and one of its subsidiaries entered into a second amendment to its loan and security agreement with Oxford Finance LLC (the “ Second Amendment ”) increasing the amount available for draw at Lexicon’s option under the third tranche from $50 million to $75 million and decreasing the amount available for draw at Lexicon’s option, subject to Oxford’s consent, under the fourth tranche from $50 million to $25 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000019/0001062822-23-000019-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Value","value":"Third tranche increased from $50M to $75M; fourth tranche decreased from $50M to $25M; minimum cash"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}